The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
Recent advances in siRNA delivery mediated by lipid-based nanoparticles
Open accessAbstract
Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the treatment of broad-spectrum intractable diseases. However, its unfavorable properties such as easy degradation in the blood and negative-charge density are still a formidable barrier for clinical use. For disruption of this barrier, siRNA delivery technology has been significantly advanced in the past two decades. The approval of Patisiran (ONPATTRO™) for the treatment of transthyretin-mediated amyloidosis, the first approved siRNA drug, is a most important milestone. Since lipid-based nanoparticles (LNPs) are used in Patisiran, LNP-based siRNA delivery is now of significant interest for the development of the next siRNA formulation. In this review, we describe the design of LNPs for the improvement of siRNA properties, bioavailability, and pharmacokinetics. Recently, a number of siRNA-encapsulated LNPs were reported for the treatment of intractable diseases such as cancer, viral infection, inflammatory neurological disorder, and genetic diseases. We believe that these contributions address and will promote the development of an effective LNP-based siRNA delivery system and siRNA formulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–206 of 206
Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice
Avivi, I. M., & Goy, A. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0488 · Cited by 21
Boyapalle, S., Xu, W., Raulji, P., Mohapatra, S., & Mohapatra, S. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135288 · Cited by 21
Koide, H., Asai, T., Kato, H., et al. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.09.003 · Cited by 19
Self-citationO’Mary, H. L., Hanafy, M. S., Aldayel, A. M., Valdes, S. A., Alzhrani, R. F., Hufnagel, S., Koleng, J. J., & Cui, Z. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00629 · Cited by 17
Roth, C. M. (2007) · Biotechnology Progress · doi:10.1021/bp070128l · Cited by 10
REVIEW ON NANOPARTICLES USED IN COSMETICS AND DERMAL PRODUCTS
Patwekar, S. L., Gattani, S. G., Giri, R., Bade, A., Sangewar, B., & Raut, V. (2014) · Cited by 10
Cited by
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
Kumar, S., Duan, Q., Wu, R., Harris, E. N., & Su, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113869 · Cited by 351
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Metadata
- Authors
- Yonezawa, S., Koide, H., & Asai, T.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 154-155
- Pages
- 64-78
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3047437072
- Cited by
- 378
- References
- 206
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.